CN114585746A - 药物毒性评价方法 - Google Patents

药物毒性评价方法 Download PDF

Info

Publication number
CN114585746A
CN114585746A CN202080072620.XA CN202080072620A CN114585746A CN 114585746 A CN114585746 A CN 114585746A CN 202080072620 A CN202080072620 A CN 202080072620A CN 114585746 A CN114585746 A CN 114585746A
Authority
CN
China
Prior art keywords
drug
cells
toxicity
organoid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080072620.XA
Other languages
English (en)
Chinese (zh)
Inventor
武部贵则
佐伯宪和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Yokohama City University
Original Assignee
Takeda Pharmaceutical Co Ltd
Yokohama City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, Yokohama City University filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN114585746A publication Critical patent/CN114585746A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/237—Oncostatin M [OSM]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202080072620.XA 2019-10-17 2020-10-16 药物毒性评价方法 Pending CN114585746A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-189838 2019-10-17
JP2019189838 2019-10-17
PCT/JP2020/039023 WO2021075528A1 (ja) 2019-10-17 2020-10-16 薬物毒性評価方法

Publications (1)

Publication Number Publication Date
CN114585746A true CN114585746A (zh) 2022-06-03

Family

ID=75537427

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080072620.XA Pending CN114585746A (zh) 2019-10-17 2020-10-16 药物毒性评价方法

Country Status (6)

Country Link
US (1) US20240125767A1 (cg-RX-API-DMAC7.html)
EP (1) EP4047082A4 (cg-RX-API-DMAC7.html)
JP (1) JP7738296B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220083699A (cg-RX-API-DMAC7.html)
CN (1) CN114585746A (cg-RX-API-DMAC7.html)
WO (1) WO2021075528A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117230145A (zh) * 2023-09-15 2023-12-15 上海交通大学医学院 一种化学品发育毒性检测方法及评估模型的构建方法与应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240110155A1 (en) * 2020-12-17 2024-04-04 Genome Biologics Ug A dual cardiac-blood model system for disease modelling and drug screening
KR102511631B1 (ko) * 2022-06-15 2023-03-20 오가노이드사이언스 주식회사 Pbmc 유래 세포독성 t 세포의 신규 용도
JPWO2024157891A1 (cg-RX-API-DMAC7.html) * 2023-01-24 2024-08-02
JPWO2025009590A1 (cg-RX-API-DMAC7.html) * 2023-07-06 2025-01-09
CN117757885A (zh) * 2023-12-26 2024-03-26 首都医科大学 一种基于高内涵的肠道菌群代谢物筛选方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017110724A1 (ja) * 2015-12-24 2017-06-29 公立大学法人横浜市立大学 血液細胞を用いた組織・臓器の作製方法
WO2017216113A2 (en) * 2016-06-15 2017-12-21 Mimetas B.V. Cell culture device and methods
WO2018035138A1 (en) * 2016-08-15 2018-02-22 Organovo, Inc. Three dimensional bioprinted tumor models for drug testing

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5841760A (ja) 1981-09-01 1983-03-11 旭化成株式会社 繊維状ヒレブランダイト及びその製造方法
WO2012166630A2 (en) 2011-05-27 2012-12-06 Xenotech Llc In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes
SG11201606750UA (en) 2014-02-27 2016-10-28 Public Univ Corp Yokohama City Method for generating cell condensate for self-organization
JP6516255B2 (ja) 2015-04-17 2019-05-22 国立大学法人東北大学 アレルギー型薬物性肝障害の評価方法
US20170285002A1 (en) 2016-03-16 2017-10-05 Public University Corporation Yokohama City University Method for reconstituting tumor with microenvironment
JP2019129707A (ja) 2016-05-19 2019-08-08 株式会社サイフューズ ヒト由来細胞を含むヘテロスフェロイド
EP3936610A1 (en) 2016-05-25 2022-01-12 Salk Institute for Biological Studies Compositions and methods for organoid generation and disease modeling
GB201622149D0 (en) 2016-12-23 2017-02-08 Insphero Ag Screenable liver disease models and methods
WO2018218344A1 (en) 2017-05-29 2018-12-06 Stemcell Technologies Canada Inc. Compositions and methods for obtaining organoids
GB201721615D0 (en) * 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
WO2019131938A1 (ja) * 2017-12-27 2019-07-04 国立研究開発法人国立成育医療研究センター 機能的肝前駆細胞もしくは肝細胞または機能的小腸上皮前駆細胞もしくは小腸上皮細胞を調製する方法
EP3927807A1 (en) * 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of generating organoids for high throughput screening of drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017110724A1 (ja) * 2015-12-24 2017-06-29 公立大学法人横浜市立大学 血液細胞を用いた組織・臓器の作製方法
WO2017216113A2 (en) * 2016-06-15 2017-12-21 Mimetas B.V. Cell culture device and methods
WO2018035138A1 (en) * 2016-08-15 2018-02-22 Organovo, Inc. Three dimensional bioprinted tumor models for drug testing

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117230145A (zh) * 2023-09-15 2023-12-15 上海交通大学医学院 一种化学品发育毒性检测方法及评估模型的构建方法与应用

Also Published As

Publication number Publication date
KR20220083699A (ko) 2022-06-20
US20240125767A1 (en) 2024-04-18
EP4047082A1 (en) 2022-08-24
JP7738296B2 (ja) 2025-09-12
WO2021075528A1 (ja) 2021-04-22
EP4047082A4 (en) 2023-08-16
JPWO2021075528A1 (cg-RX-API-DMAC7.html) 2021-04-22

Similar Documents

Publication Publication Date Title
JP7738296B2 (ja) 薬物毒性評価方法
Levescot et al. IL-1β–driven osteoclastogenic Tregs accelerate bone erosion in arthritis
Beilmann et al. Application of new approach methodologies for nonclinical safety assessment of drug candidates
Shi et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function
Adams et al. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia
Kralova Lesna et al. Characterisation and comparison of adipose tissue macrophages from human subcutaneous, visceral and perivascular adipose tissue
Syn et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease
Bahlmann et al. Erythropoietin regulates endothelial progenitor cells
Mion et al. Mast cells control the expansion and differentiation of IL-10–competent B cells
Gehmert et al. Angiogenesis: the role of PDGF-BB on adiopse-tissue derived stem cells (ASCs)
Klein et al. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
Fan et al. Interleukin‐1β augments the angiogenesis of endothelial progenitor cells in an NF‐κB/CXCR7‐dependent manner
Cannito et al. Fibroinflammatory liver injuries as preneoplastic condition in cholangiopathies
Bajetto et al. Metformin potentiates immunosuppressant activity and adipogenic differentiation of human umbilical cord-mesenchymal stem cells
Park et al. Three-dimensional organoids as a model to study nonalcoholic fatty liver disease
Cirillo et al. Human Sarcopenic Myoblasts Can Be Rescued by Pharmacological Reactivation of HIF-1α
Smith et al. Distinct characteristics of microglia from neurogenic and non-neurogenic regions of the human brain in patients with Mesial Temporal Lobe Epilepsy
WO2010103058A1 (en) Method or system using biomarkers for the monitoring of a treatment
Barthelmes et al. Diabetes impairs mobilization of mouse bone marrow-derived Lin−/VEGF-R2+ progenitor cells
Shiba et al. Bone marrow CXCR4 induction by cultivation enhances therapeutic angiogenesis
Kuver et al. Murine gallbladder epithelial cells can differentiate into hepatocyte-like cells in vitro
Waterbury et al. Bone marrow neutrophil density regulates myelopoiesis during obesity and weight loss
Bird et al. In vitro sepsis induces Nociceptin/Orphanin FQ receptor (NOP) expression in primary human vascular endothelial but not smooth muscle cells
Jiang et al. [Retracted] Scolopendra subspinipes mutilans L. Koch Ameliorates Rheumatic Heart Disease by Affecting Relative Percentages of CD4+ CD25+ FoxP3 Treg and CD4+ IL17 T Cells
Maraldi et al. Human biliary tree stem/progenitor cells immunomodulation: role of hepatocyte growth factor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220603

WD01 Invention patent application deemed withdrawn after publication